The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy

Anne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja · 2025

Read The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy by Anne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12785806.txt.

Description

Anne-Line Mayland Madsen and co-authors test whether scan-based markers predict outcomes for high-risk melanoma patients given immune therapy after surgery. The therapy improves freedom from recurrence but causes side effects in many. Scans that track sugar use in tissue might flag immune side effects and organ activity ratios tied to outlook.

In a Danish register cohort, over half the patients saw their cancer return and a quarter died during follow-up. Most showed at least one scan-detected immune side effect. Those side effects did not predict overall survival, and early ones were linked to higher recurrence risk, opposite to some prior reports. Ratios for spleen and bone marrow showed no prognostic value.

Catalog record

CREATORAnne-Line Mayland Madsen, Oke Gerke, Christina H. Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12785806

Browse the full library · About the Tower of Babel